Competition & Markets Authority
Drug firms admit to colluding in order to keep prices up
Two suppliers of the antidepressant, nortriptyline, have admitted illegally sharing information in order to keep prices up.
The move comes as part of a competition law investigation by the Competition and Markets Authority (CMA) into drug firms King Pharmaceuticals Limited, Alissa Healthcare Research Limited and Lexon (UK) Limited.
In June 2019, the CMA issued a statement of objections provisionally finding that the 3 suppliers had exchanged commercially sensitive information about prices, volumes and entry plans in order to keep prices up.
Nortriptyline is prescribed by the NHS and relied on by thousands of patients every month to relieve the symptoms of depression. NHS spending on the drug peaked at £38 million in 2015.
King and Alissa have now admitted breaking competition law by exchanging strategic and competitively-sensitive information with one another and with Lexon during periods between 2015 and 2017.
The CMA’s investigation into Lexon is ongoing as the firm denies involvement in the suspected infringement. Therefore, any infringement decision - which could lead to a fine - would be made at the end of the investigation.
For more information see the case page.
Latest News from
Competition & Markets Authority
CMA secures loan write-off from payday lender07/07/2020 13:48:00
Following CMA action, payday lender Shelby Finance has written off loans and apologised to customers after not providing them with important information.
Court orders disqualification of estate agent cartel director06/07/2020 10:05:00
In the first contested case of its kind, the CMA has secured the disqualification of a director whose Somerset estate agency breached competition law.
COVID-19: CMA secures refunds from second major holiday lets firm03/07/2020 13:20:00
Following an investigation by the CMA, Sykes Cottages has reversed its policy on cancelled bookings and will now offer customers full refunds.
Latest update from CMA COVID-19 taskforce03/07/2020 12:20:00
The CMA has published a third update from its COVID-19 taskforce, which monitors and responds to competition and consumer problems arising from the pandemic.
CMA imposes £1.2m in fines for price-fixing in private eyecare02/07/2020 09:20:00
The CMA has found that a private hospital group and 7 consultant ophthalmologists broke competition law by taking part in illegal price fixing.
New regime needed to take on tech giants01/07/2020 15:02:00
The CMA is calling on the government to introduce a new pro-competition regulatory regime to tackle Google and Facebook’s market power.
Medical device suppliers’ merger raises competition concerns01/07/2020 09:15:00
The CMA has concluded that the merger of 2 suppliers of medical devices could lead to a reduction of competition in the supply of total ankle replacement prosthetics.
Musical instrument firms to pay millions after breaking competition law30/06/2020 12:20:00
The CMA has fined 2 musical instrument makers a total of £5.5 million, in 2 separate cases, for breaking competition law by restricting online discounting of musical instruments.